Not for distribution by US newswire or in United States

NESS-ZIONA, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSXV:VXL) is pleased to announce that the Company, further to it's news release from October 29, 2025, that it has revised the terms of its previously announced offering and now intends to complete a non-brokered private placement on a commercially reasonable efforts basis (the "Offering") of up to 3,111,111 units ("Units") of the Company at a price of $0.1125 per Unit to raise gross proceeds of up to $350,000. Each Unit will consist of one common share of the Company ("Shares") and one Share purchase warrant ("Warrants"). Each Warrant will entitle the holder to acquire one additional Share at a price of $0.15 per Share for a period of five years following the closing of the Offering.

Net proceeds from the Offering will be used by the Company to support general corporate purposes.

The closing of the Offering is subject to a number of conditions, including but not limited to, approval by the TSX Venture Exchange of the Offering.

The Company expects the Offering to close on ...